Merck has bolstered its oncology pipeline with its latest licensing agreement with Orion, where the two companies will co-develop and co-commercialise an experimental prostate cancer drug. The deal also comes with the opportunity to convert the agreement into an exclusive licence for Merck, which would bring future milestone payments and royalties for Orion. The drug, ODM-208, is currently in Phase II trials for metastatic castration-resistant prostate cancer.
Download this edition of Cancer Drug News to get more on this story and additional insight on the companies and research organisations shaping the industry, including:
- US FDA Defers Action On BeiGene's BLA For Tislelizumab As Second-Line Treatment Of ESCC
- ODD Granted To NeoImmuneTech's NT-I7 For GBM Treatment
- Omega Earns FDA Approval For IND Of Its OTX-2002 For HCC Treatment
- First Patient Dosed In LOTIS-5 Phase III DLBCL Trial Of ZYNLONTA Plus Rituximab In Mainland China
- Exelixis Meets Primary Endpoint Of PFS In Ongoing COSMIC-313 Phase III RCC Pivotal Trial